All In Biotech

Drug Trial Radar · NCT05861297

Immune Thrombocytopenia Management in Adults

The Outcomes and Safety of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients With Hemorrhage Comorbidity

Last checked: Nov 20, 2026Latest source record: May 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 467 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

467

Planned (sponsor's estimate)

Start

May 5, 2020

Primary completion

Jan 18, 2024

Study completion Apr 2, 2024

Sponsor

Lead sponsor
Nahda UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Immune thrombocytopenia treatment has evolved recently. However, none of treatments have only benefits without drawbacks. This study compares the clinical outcomes and adverse drug patterns of different treatment options. Medications which will be assessed during the current study are High Dose-dexamethasone (HD-DXM) (control group), Prednisolone + Azathioprine, Rituximab, Eltrombopag, and Romiplostim.

Conditions

  • Immune Thrombocytopenia Purpura

Interventions

  • DexamethasoneDrug

    Patients were initiated with High Dose-Dexamethasone with a dose of 40 mg/m2 daily for four days per week immediately after the diagnosis of ITP for 6 months

  • Prednisolone and AzathioprineDrug

    the second group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months.

  • RituximabDrug

    The third group received 500 mg/m2 intravenously of Rituximab once weekly for one month

  • EltrombopagDrug

    The fourth group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months

  • RomiplostimDrug

    The fifth group received 3μg/kg subcutaneous injection of Romiplostim once a week for 6 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. total patients who achieved sustained and overall responseTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EL-Kasr elineiy

    Cairo, Egypt · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.